---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-076627"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:45:47.281272+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Janux reports FY2025 net loss $113.6M; cash $966.6M; BMS collaboration with $50M upfront

## Summary
- Cash and short-term investments $966.6M at Dec 31, 2025, down from $1.03B a year ago.
- R&D expenses $125.9M for FY2025 vs $68.4M; net loss $113.6M vs $69.0M in 2024.
- Entered collaboration with Bristol Myers Squibb for tumor-activated therapeutic; $50M upfront + up to $800M milestones.
- Appointed Dr. William Go as CMO; JANX007/008/011 trials continue enrolling.

## SEC filing metadata
- accession: 0001193125-26-076627
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000119312526076627/0001193125-26-076627-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000119312526076627/janx-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-076627
- JSON: https://secwatch.observer/filing/0001193125-26-076627.json
- Plain text: https://secwatch.observer/filing/0001193125-26-076627.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.